ARTICLE | Politics, Policy & Law
CBO asked to consider impacts on post-approval indications, delays in launching smaller indications, effects on generic, biosimilar competition
By Steve Usdin, Washington Editor
November 22, 2023 12:28 AM UTC
Republican members of Congress have asked the Congressional Budget Office a series of pointed questions about its analysis of the impacts of the Inflation Reduction Act’s Medicare drug negotiation program. The questions reflect biopharma industry concerns that CBO’s projections drastically understate the effects of the IRA on drug development.
In a Nov. 20 letter, Rep. Michael Burgess (R-Texas), chair of House Budget Committee’s Health Care Task Force, and Jodey Arrington, chairman of the Budget Committee, asked if CBO is “tracking trends in investments in early-stage drug development by venture capital firms following the passage of the IRA.”…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650732/gop-asks-cbo-to-address-concerns-about-the-ira